Human erythrocytes and A549 non-small cell lung adenocarcinoma cells

Human erythrocytes and A549 non-small cell lung adenocarcinoma cells are distinct biological entities frequently employed as experimental models in pharmacological and toxicological research. Human erythrocytes (red blood cells) are enucleated cells specialized for oxygen and carbon dioxide transport; they serve as a standard model for assessing drug-induced hemolysis and membrane stability (1). A549 cells are a well-characterized human cell line derived from a lung adenocarcinoma, exhibiting features of alveolar Type II pneumocytes, and are extensively used to study lung cancer biology and drug efficacy (2). In many studies, these two cell types are used together to determine the therapeutic index of a compound by measuring its ability to kill cancer cells (A549) while sparing healthy blood cells (erythrocytes) (3). This entry does not refer to a specific molecular target such as a receptor or enzyme, but rather to the cellular systems used to evaluate drug activity. (1) https://pmc.ncbi.nlm.nih.gov/articles/PMC3312014/ (2) https://www.atcc.org/products/ccl-185 (3) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744574/

Other names

Red blood cellsRBCsA549 cellsAdenocarcinomic human alveolar basal epithelial cellsA549 cell line

Not applicable as this entry describes cell-based assay systems rather than a specific molecular target.